Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document.
about
Pain management strategies for neuropathic pain in Fabry disease--a systematic reviewReview and evaluation of the methodological quality of the existing guidelines and recommendations for inherited neurometabolic disordersTime to treatment benefit for adult patients with Fabry disease receiving agalsidase β: data from the Fabry Registry.Correlations between Endomyocardial Biopsies and Cardiac Manifestations in Taiwanese Patients with the Chinese Hotspot IVS4+919G>A Mutation: Data from the Fabry Outcome Survey.Ultrastructural deposits appearing as "zebra bodies" in renal biopsy: Fabry disease?- comparative case reports.Exploratory screening for Fabry's disease in young adults with cerebrovascular disorders in northern Sardinia.Cardiac Troponin I: A Valuable Biomarker Indicating the Cardiac Involvement in Fabry Disease.Uric Acid as a Marker of Mortality and Morbidity in Fabry Disease.The Large Phenotypic Spectrum of Fabry Disease Requires Graduated Diagnosis and Personalized Therapy: A Meta-Analysis Can Help to Differentiate Missense MutationsUrinary Podocyte Loss Is Increased in Patients with Fabry Disease and Correlates with Clinical Severity of Fabry Nephropathyp.R301X Mutation and Variable Phenotypic Appearance of Fabry Disease.Multicenter Female Fabry Study (MFFS) - clinical survey on current treatment of females with Fabry disease.Gender Differences in the Application of Spanish Criteria for Initiation of Enzyme Replacement Therapy for Fabry Disease in the Fabry Outcome Survey.Genetic Screening of Mutations Associated with Fabry Disease in a Nationwide Cohort of Juvenile Idiopathic Arthritis Patients.Fabry Disease: Recognition, Diagnosis, and Treatment of Neurological Features.Characterization of Classical and Nonclassical Fabry Disease: A Multicenter Study.Renal function predicts long-term outcome on enzyme replacement therapy in patients with Fabry disease.Retrospective study of long-term outcomes of enzyme replacement therapy in Fabry disease: Analysis of prognostic factorsSerum Bilirubin Levels and Promoter Variations in HMOX1 and UGT1A1 Genes in Patients with Fabry Disease.Fabry disease due to D313Y and novel GLA mutations.Current and Future Treatments for Lysosomal Storage Disorders.Cardiac and renal dysfunction is associated with progressive hearing loss in patients with Fabry disease.E-Learning for Rare Diseases: An Example Using Fabry Disease.Enzyme replacement therapy in a patient of heterozygous Fabry disease: clinical and pathological evaluations by repeat kidney biopsy and a successful pregnancy.Clinical-Pathological Conference Series from the Medical University of Graz : Case No 153: A 55-year-old woman with atypical multiple sclerosis and irritable bowel syndrome.Globotriaosylsphingosine (Lyso-Gb3) as a biomarker for cardiac variant (N215S) Fabry disease.Neuropathic pain in a Fabry disease rat model.Consensus clinical management guidelines for Niemann-Pick disease type C.Limited effects of long-term enzyme replacement therapy on the cardiac conduction system in Fabry diseaseCharacterization of vertigo and hearing loss in patients with Fabry disease
P2860
Q26766561-5469E5B4-B637-486C-ACF8-7EF5194B0FADQ26771677-CC7ADF56-8160-49B8-8B8C-990B3E70675AQ31060724-D2E03912-70BB-4A41-BE5C-047AE6BF4741Q31154163-1DDC9E46-33E9-4A03-90A5-1175335E5728Q33667541-79F5FA5D-B703-40EE-AD97-B6C2DEFC84C3Q35865045-D5F122C7-96E3-42A9-9C64-62E68E69FF0CQ36056601-E6D981F7-EE13-4413-9260-46B8D2C0D038Q36189989-274D9853-0492-4CE2-AB11-3C2D76927B72Q36213022-736AE22D-C73A-4E27-ABD8-3A28A8DD5A77Q36228560-137F096E-9086-4FD6-A0D6-99BD12822458Q37020755-06F0B765-4CFD-4A98-BB85-098FF465BB46Q37054755-DE908EA5-775A-4136-AC1B-0750FFAADE1DQ37534497-9DAB09B1-D1BA-4981-B60E-E194F5958EB7Q37672375-08D13474-98EE-4B89-B114-0B761972F725Q38844401-4A424517-175D-4F9A-AFC9-244AF0E16123Q39097273-EE925BED-227C-440B-A508-605FF4A1671BQ39344648-22EEDF1B-4777-481F-923B-45B6955C4069Q41200738-50A98779-65A5-4B2E-A827-4544EE97A520Q41689988-C3CB1E26-1020-4DD0-9AE5-F96A0BC39844Q42376825-55251D1F-F6C2-46FD-9837-3EDA579AABEBQ45873942-9A23425D-01C1-4A6C-9704-E2219A4DF0AEQ47134914-BF61568D-87B6-42AD-89B5-7BA7AFE2CCB1Q47147113-3206AD3E-5C5D-436D-BE89-A22D093A5C59Q47155938-8F458017-8166-4C64-BC80-417C0C304CFCQ47209693-F0E0BC38-0CE4-4882-AEFF-F413C15FC413Q47886623-05FEA53A-C531-49B7-9F4E-A3CBAE1EC5E4Q52347263-1BD5FBDA-3975-4134-AC0E-C72E2A72AA52Q52602028-9BB44A7D-1F93-4C7B-8146-AB7EE26C1423Q57148060-C063AB88-922A-4430-84E9-47281A964DDAQ58778007-D6002EE0-236A-4596-9DA2-135AEA443477
P2860
Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document.
description
2015 nî lūn-bûn
@nan
2015 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի մարտին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Recommendations for initiation ...... king Group consensus document.
@ast
Recommendations for initiation ...... king Group consensus document.
@en
type
label
Recommendations for initiation ...... king Group consensus document.
@ast
Recommendations for initiation ...... king Group consensus document.
@en
prefLabel
Recommendations for initiation ...... king Group consensus document.
@ast
Recommendations for initiation ...... king Group consensus document.
@en
P2093
P2860
P50
P1476
Recommendations for initiation ...... rking Group consensus document
@en
P2093
Andreas Serra
Annelies Sweeb
Atul Mehta
Bojan Vujkovac
Camilla Tøndel
Carla E M Hollak
Christine Lavery
Claudia Sommer
Einar Svarstad
Erica van de Mheen
P2860
P2888
P356
10.1186/S13023-015-0253-6
P50
P577
2015-03-27T00:00:00Z
P5875
P6179
1026151758